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AbstrAct
Background: Whether bevacizumab exerts its anti-tumor properties through 
systemic effects beyond local inhibition of angiogenesis and how these effects can 
be monitored in patients, remain largely elusive. To address these questions, we 
investigated bone marrow-derived cells and cytokines in the peripheral blood of 
metastatic breast cancer patients undergoing therapy with bevacizumab.
Methods: Circulating endothelial cells (CEC), circulating endothelial progenitor 
(CEP) and circulating CD11b+ cells in metastatic breast cancer patients before and 
during therapy with paclitaxel alone (n = 11) or in combination with bevacizumab 
(n = 10) were characterized using flow cytometry, real time PCR and RNASeq. 
Circulating factors were measured by ELISA. Aged-matched healthy donors were 
used as baseline controls (n = 12).
Results: Breast cancer patients had elevated frequencies of CEC, CEP, 
TIE2+CD11b+ and KIT+CD11b+ cell subsets. CEC decreased during therapy, irrespective 
of bevacizumab, while TIE2+CD11b+ remained unchanged. KIT+CD11b+ cells decreased 
in response to paclitaxel with bevacizumab, but not paclitaxel alone. Cancer patients 
expressed higher mRNA levels of the M2 polarization markers CD163, ARG1 and IL-10 
in CD11b+ cells and increased levels of the M2 cytokines IL-10 and CCL20 in plasma. 
M1 activation markers and cytokines were low or equally expressed in cancer patients 
compared to healthy donors. Chemotherapy with paclitaxel and bevacizumab, but not 
with paclitaxel alone, significantly decreased IL-10 mRNA in CD11b+ cells and IL-10 
protein in plasma. 
Conclusions: This pilot study provides evidence of systemic immunomodulatory 
effects of bevacizumab and identified circulating KIT+CD11b+ cells and IL-10 as 
candidate biomarkers of bevacizumab activity in metastatic breast cancer patients. 
INtrODUctION
Growing experimental evidence indicates that tumors 
can mobilize a diverse spectrum of bone marrow derived 
(BMD) and inflammatory cells and recruit them to the 
primary and metastatic tumor microenvironments. Upon 
recruitment these cells are educated to support cancer cell 
proliferation, survival and invasion and to induce tumor 
angiogenesis and matrix remodeling [1]. Mobilization and 
recruitment of BMD and inflammatory cells have also been 
associated with resistance to anti-cancer therapy, including 
anti-angiogenic therapy [2]. Among these cells, endothelial 
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progenitor cells and BMD myelomonocytic cells have 
received particular attention in relationship to resistance 
to therapy [1, 3]. It has been reported that chemotherapy 
mobilizes endothelial progenitor cells, thereby favoring 
tumor angiogenesis, while concomitant anti-angiogenic 
therapy blunts this mobilization and enhances response 
to chemotherapy [4]. Blockade of monocyte/macrophage 
recruitment in combination with chemotherapy was 
shown to reduce tumor growth and improve survival of 
mammary tumor-bearing mice compared to chemotherapy 
alone [5]. Strikingly, anti-angiogenic therapy itself was 
reported to mobilize BMD CD11b+ myelomonocytic cell 
sub-populations with pro-angiogenic properties, thereby 
contributing to resistance to anti-angiogenic therapy [6]. 
Therefore, it has been proposed that therapy-mobilized 
BMD myelomonocytic cells and circulating endothelial 
progenitor cells (CEP) could serve as biomarkers of 
resistance to therapy as well as therapeutic targets to 
elude resistance [7]. In addition, circulating endothelial 
cells (CEC) were shown to be present at higher levels in 
the peripheral blood of cancer patients and to represent a 
potential biomarker for angiogenic, unstable vessels and 
vascular disruption by therapy [3]. The role of mobilized 
BMD cells, in particular CD11b+ cells and CEP, in predicting 
response and/or mediating resistance to therapy in human 
cancer remains undefined. We previously reported increased 
levels of CEC in breast cancer patients, which decreased 
during chemotherapy, whereas CEP increased during 
chemotherapy [8]. Increase in VEGFR2+ CEP was shown 
to predict relapse in non-metastatic breast cancer patients 
and disease progression in metastatic patients [9]. Increased 
levels of circulating CD11b+ myeloid-derived suppressor 
cells were reported in breast cancer and other malignancies, 
and were shown to correlate with cancer stage, metastatic 
burden and chemotherapy treatment [10–12]. 
Anti-VEGF therapy with bevacizumab, alone or in 
combination with chemotherapy, is now standard in several 
types of advanced/metastatic cancers [13]. At present 
however the mechanisms of action of bevacizumab is still 
matter of investigation and no biomarkers of activity or 
prediction of response have been identified [14]. Both 
subjects are clinically relevant, as only a fraction of 
patients initially respond to bevacizumab and most of them 
eventually develop resistance thereby resulting in limited 
overall survival benefits [15, 16]. 
A few studies investigated blood-circulating factors 
in several cancers, such as non-small-cell lung cancer 
(NSCLC) [17], metastatic colorectal cancer [15, 18, 19] 
and advanced pancreatic cancer [20] in relationship with 
bevacizumab therapy, and identified candidate biomarkers 
of response or outcome. Additional studies explored the 
effect of bevacizumab on circulating CEC, CEP and 
CD11b+ myelomonocytic cells and the relationship to 
patients’ response to therapy [21–23]. 
A further characterization of bevacizumab effects 
on circulating cells might allow a more complete 
understanding of its mechanism of actions and possibly 
defining biomarkers for predicting or monitoring the 
response to treatment. In this pilot study we analyzed 
the frequency and phenotype of CEC, CEP and selected 
CD11b+ cell subsets in breast cancer patients diagnosed 
with metastasis before and during the first cycle of therapy 
with paclitaxel ± bevacizumab. To further characterize 
CD11b+ cells we performed gene expression analysis 
by RNASeq and validate expression of selected genes at 
mRNA and protein levels by real time qPCR and ELISA. 
rEsULts 
Metastatic breast cancer patients have elevated 
frequency of cEc and cEP
First we quantified the frequency of CEC and CEP 
in the blood of 21 metastatic breast cancer (mBC) patients 
and 12 age-matched healthy donors by cell surface 
staining and flow cytometry following the protocol by 
Bertolini et al. [24, 25] (Table 1). CEC were defined as 
CD45−DNA+CD146+CD31+ cells and CEP as CD45−
DNA+CD133+CD34+ cells. Compared to healthy donors, 
breast cancer patients had elevated levels of CEC and 
CEP (Figure 1A–1B). CEPs in mBC patients were also 
significantly more positive for VEGFR2 expression 
compared to healthy donors (Figure 1C). Surprisingly the 
fraction of dying CEP, but not CEC, determined using 
7AAD+ permeability staining, was significantly higher in 
mBC patients (Figure 1D–1E). 
bevacizumab treatment has no additional effect 
on cEc and cEP over paclitaxel chemotherapy
To monitor the effect induced by paclitaxel ± 
bevacizumab on circulating CEC and CEP, we analyzed blood 
from 11 patients upon breast metastasis detection treated first 
line with one cycle of paclitaxel chemotherapy alone and 
from 10 patients treated with paclitaxel in combination with 
bevacizumab. Blood was taken before therapy start (day 0) 
and at days 8 and 15 immediately before the administration 
of the treatment. Under chemotherapy the frequency of 
CEC dropped by over 80% regardless of the presence of 
bevacizumab (Figure 1F, left panel). The number of CEP 
doubled at day 8 of therapy with paclitaxel and bevacizumab 
(although the difference is not statistically significant due to 
large variability in the values) and returned to normal at day 
15. Therapy with paclitaxel alone had no effect.
These data demonstrate the presence of elevated levels 
of blood circulating CEC and CEP in patients with mBC, and 
that bevacizumab treatment has no effect on their frequency 
in addition to chemotherapy at the investigated time points. 
Increased frequency of circulating tIE2+cD11b+ 
and KIt+cD11b+ cells in mbc patients
We previously observed elevated levels of 
VEGFR1+CD11b+ [26], KIT+CD11b+ [27] and JAM1+CD11b+ 
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(unpublished data) in murine models of breast cancer and 
TIE2+CD11b+ cells in mBC cancer patients [28]. We therefore 
hypothesized that the frequency of CD11b+ cells and subsets 
thereof could potentially reflect the presence of a tumor 
and possibly patients’ response to the treatment. To test this 
hypothesis we used flow cytometry to measure CD11b+ cell 
subsets in healthy donors and in patients with mBC before 
and during therapy. Frequencies of circulating TIE2+CD11b+ 
and KIT+CD11b+ cells, but not VEGFR1+CD11b+ or 
JAM1+CD11b+ cells were significantly elevated in mBC 
patients compared to healthy donors (Figure 2A–2D). JAM1+ 
or VEGFR1+ cells represented a large fraction of the CD11b+ 
cell population (approx. 90% and 70%, respectively). In 
contrast, the relative frequency of TIE2+ cells within the 
CD11b+ cells was very low (< 1% in average), and that of 
KIT+ cells was spread over a large spectrum, ranging from 
2–5% to 60% of the CD11b+ cells. Importantly, KIT+CD11b+ 
cells were extremely rare in healthy donors (0.3% of 
CD11b+ cells). 
As we observed a large variation of KIT protein 
expression at the cell surface of mBC patients, we tested 
whether KIT mRNA expression in CD11b+ blood cells 
was more homogeneous. CD11b+ cells were isolated from 
fresh blood of mBC patients and healthy donors by MACS 
technology and analyzed for KIT mRNA levels by qPCR. 
Purity of isolated CD11b+ cells was > 98% (Supplementary 
Figure 1). Surprisingly results revealed that KIT mRNA 
expression levels were very low in mBC patients and 
indistinguishable from healthy donors (Supplementary 
Figure 2). 
Figure 1: Increased frequency of cEc and cEP in the blood of metastatic breast cancer patients. Quantification of (A) 
CEP, (b) CEC, (c) CEP expressing VEGFR2, (D) dying CEP using 7AAD staining, and (E) dying CEC using 7AAD staining in the 
blood of healthy donors and metastatic breast cancer patient before therapy start. (F) Quantification of CEC and CEP under chemotherapy 
± bevacizumab treatments in the blood of metastatic breast cancer patients. Cell quantifications were performed by flow cytometry and data 
are represented as mean +/− SD. 
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bevacizumab reduces the frequency of 
circulating KIt+cD11b+ in paclitaxel-treated 
patients
Next we measured the effect of therapy on CD11b+ 
cell subsets. Therapy with ± bevacizumab did not 
significantly alter the frequency of VEGFR1+CD11b+, 
JAM1+CD11b+ or TIE2+CD11b+ cells (Figure 2E–2G). In 
contrast, therapy with paclitaxel caused a significant 2-fold 
increase in the frequency of circulating KIT+CD11b+ cells 
at day 15, while addition of bevacizumab resulted in a 
significant drop (60–80%) at days 8 and 15 (Figure 2H).  
From these experiments we concluded that circulating 
TIE2+CD11b+ and KIT+CD11b+ cells are enriched in 
mBC, and bevacizumab decreases KIT+CD11b+, but not 
TIE2+CD11b+ cells.
Figure 2: Increased frequency of tIE2+cD11b+ and KIt+cD11b+ cells in the blood of metastatic breast cancer patients 
and decreased frequency of KIt+cD11b+ cells by bevacizumab therapy. Quantification of CD11b+ cells expressing (A) 
VEGFR1, (b) JAM1, (c) TIE2 and (D) KIT in the blood of healthy donors and breast cancer patients before therapy start. Quantification 
under both chemotherapy treatments of CD11b+ cells expressing (E) VEGFR1, (F) JAM1, (G) TIE2 and (H) KIT in the blood of metastatic 
breast cancer patients. Cell quantifications were performed by flow cytometry and data are represented as mean +/− SD.
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circulating cD11b+ cells in mbc patients have 
a distinctive gene expression profile compared to 
healthy donors
To further characterize CD11b+ cells in mBC 
patients we performed RNASeq analysis on CD11b+ cells 
isolated from 4 healthy donors and 4 cancer patients. 
Principal Component Analysis (PCA) revealed that 
the gene expression profiles of CD11b+ cells derived 
from mBC patients clustered together while those from 
CD11b+ cells derived from healthy donors were dispersed 
(Figure 3A). This result suggests that in healthy conditions 
CD11b+ cells have rather heterogeneous gene expression 
across individuals, while in cancer a re-programming takes 
place resulting in a more homogenous gene expression 
across patients. Self-organizing heat-maps confirmed that 
CD11b+ cells from cancer patients and healthy donors 
display different gene expression profiles (Figure 3B). 
Interestingly, among the most differentially expressed 
genes, we observed that CD11b+ cells from mBC patients 
expressed genes of M2 monocytes’ activation state 
(i.e. IL-10 and CCL20) (Supplementary Table 1). Gene 
ontology analysis of the differentially expressed genes 
(Figure 3C–3D and Supplementary Tables 2–3) reveled 
that expression of immune response genes was reduced in 
mBC, consistent with a M2 tumor-induced CD11b+ cells 
polarization. 
cD11b+ monocytes in mbc patient display a M2 
activation phenotype
To strengthen this observation we monitored the 
expression of additional transcripts associated with M2 
activation states in CD11b+ cells derived from healthy 
donors and mBC patients. IL-10, ARG1 and CD163, typical 
M2 activation markers, were highly up regulated in mBC 
patient (Figure 4A–4C). In contrast, the M1 activation 
markers CCR7, CD86 and IL-12a were expressed at lower 
levels, albeit not significantly (Figure 4D–4F). We also 
validated the increased expression of fibronectin mRNA in 
CD11b+ cells of mBC patients (Supplementary Table 1 and 
Supplementary Figure 3). 
From these results we concluded that circulating 
CD11b+ cells in mBC have a different gene expression 
profile compared to healthy donors, and express genes 
associated with a M2, but not M1 activation. 
Increased levels of the circulating M2 cytokines 
IL-10 and ccL20 in mbc patients
To collect additional evidence that the M2 activation 
in mBC was a systemic event, we measured selected M1 
and M2 cytokines in the plasma of healthy donors and 
mBC patients. The M1 cytokines TNFα and IL-12 were 
below detection levels, while CCL2 was detectable, but 
no differences were observed (Figure 5A). In contrast, 
the level of the M2 cytokines IL-10 and CCL20 was 
significantly higher in mBC patients compared to healthy 
donors (Figure 5B). These results corroborate the mRNA 
expression data consistent with a M2 activation state of 
circulating CD11b+ cells in mBC patients. 
bevacizumab diminishes IL-10 mrNA 
expression in cD11b+ cells and protein level in 
plasma
Next we monitored the effect of therapy on the 
elevated M2 markers. Due to limited number of CD11b+ 
cells and derived mRNA recovered form treated patients, 
we focused the analysis on a few genes only. The mRNA 
expression level of CD163 and ARG1 clearly decreased 
in cancer patients under chemotherapy regardless of 
the presence of bevacizumab, although bevacizumab 
accelerated the decrease of ARG1 (Figure 5C–5D). 
Importantly, we observed a significant decrease of IL- 10 
both at mRNA level in CD11b+ cells and at protein levels 
in the plasma of patients treated with bevacizumab in 
addition to paclitaxel (Figure 5E and 5F). Furthermore 
we observed a stronger increase in CD86 mRNA level in 
CD11b+ cells and CCL2 protein level (both reflecting M1 
activation state) in plasma of mBC patients treated with 
paclitaxel + bevacizumab compared to patients treated 
with paclitaxel only. However due to a greater variability 
and the small number of patients, differences were not 
statistically significant (Supplementary Figure 4). 
These results demonstrate that mBC patients have 
M2-activated circulating CD11b+ cells and elevated levels 
of M2 cytokines in plasma. Bevacizumab addition to 
chemotherapy causes a significant decrease of IL-10 mRNA 
levels in CD11b+ cells and IL-10 protein levels in plasma. 
DIscUssION 
The mode of action of bevacizumab is not 
yet fully understood. Beyond a rather transient anti-
angiogenic effect, a possible more complex, systemic 
effect has been proposed [29, 30]. Additionally, 
immunomodulatory effects of anti-angiogenic therapies 
have been discussed [31]. To collect evidence supporting 
systemic, immunomodulatory effects of bevacizumab, 
and to identify candidate biomarkers to predict or monitor 
response to treatment, we investigated the effect of 
bevacizumab in addition to paclitaxel, on CEC, CEP and 
CD11b+ cell subsets in the blood of mBC patients. 
Beyond the fact that CEC and CEP are present at 
higher frequency in the blood of mBC patients compared 
to healthy donors and that paclitaxel therapy decreases 
CEC independently of bevacizumab, no relationship 
between anti-angiogenic treatment and CEP behavior are 
observed. We couldn’t validate the mobilization of CEP 
by paclitaxel and the inhibitory effect by bevacizumab 
previously reported in preclinical and clinical studies 
Oncotarget11143www.impactjournals.com/oncotarget
[4, 8]. Rather we observed a transient (at day 8) but 
statistically non-significant increase of CEP in patients 
treated with paclitaxel and bevacizumab compared 
to paclitaxel treatment alone. The discrepancy of the 
observation on CEP may be due to the different time points 
analyzed (a few hours vs. 8 and 15 days after therapy start) 
and to differences in the definition and analysis of CEP 
across these studies.
In contrast, we observed a KIT+CD11b+ population 
present only in the peripheral blood of cancer patients 
and whose frequency decreased significantly under 
therapy with paclitaxel and bevacizumab compared to 
paclitaxel only. This effect is specific, as three additional 
subpopulations of CD11b+ cells (VEGFR1+, JAM1+, 
TIE2+) were not affected. We have previously reported 
that circulating KIT+CD11b+ cells promote metastasis 
Figure 3: cD11b+ myelomonocytic cells from metastatic breast cancer patients and healthy donors show different 
expression profiles. (A) PCA plot representing differential clustering of cancer patients (C1-4) and healthy donors (H1-4) based on 
mRNA expression profiles of CD11b+ cells. (b) Self-organizing heat-map of the top 100 genes with greatest variability across all samples, 
showing different expression profiles in CD11b+ cells from cancer patients compared to healthy donors. (c) Gene ontology analysis 
showing the most up-regulated biological processes comparing cancer patients and healthy donors. (D) Gene ontology analysis showing 
the most down-regulated biological processes comparing cancer patients and healthy donors.
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in the 4T1 murine model of breast cancer relapse after 
radiotherapy [27]. Little was known, however, about 
the clinical and biological significance of KIT+CD11b+ 
cells in patients. Here we demonstrate that such cells 
circulate in the blood of patients with metastatic breast 
cancer but are virtually absent in healthy individuals. 
This observation raises several questions. A critical 
one is whether KIT+CD11b+ cells might be a potential 
biomarker paralleling activity of, or predicting response 
to, bevacizumab treatment. The broad distribution of 
KIT+CD11b+ frequency suggests that patients may be 
heterogeneous in term of KIT+CD11b+ mobilization or 
recruitment. The potential therapeutic significance of 
this observation is open at this point, and further studies 
including more patients and monitoring clinical outcome 
are necessary to address it. The origin, role and fate of 
these cells in cancer progression are also intriguing. The 
discrepancy observed between levels of KIT protein and 
mRNA is consistent with immature myeloid-derived cells 
shutting down KIT expression upon mobilization. These 
cells, once in the blood circulation, may be on the way to 
differentiation and therefore no longer express KIT mRNA, 
while still carry KIT protein at the cell surface. In the 4T1 
model we reported that mobilized Kit+CD11b+ cells rapidly 
lose KIT surface expression upon adoptive transfer [27].  
The gene expression profiling of CD11b+ cells 
demonstrated significant differences between cancer patients 
and healthy donors. Strikingly, expression profiles of 
CD11b+ cells from cancer patients were more homogeneous 
compared to those of healthy donors. This is consistent 
with the functional heterogeneity CD11b+ cells in healthy 
individuals reflecting physiological individualistic behaviors 
vs. a tumor-driven CD11b+ reprogramming resulting in 
more homogenous gene expression profiles. Consistent with 
this notion, we observed the expression of transcripts for 
M2 activation markers in CD11b+ cells of cancer patients 
in comparison to CD11b+ cells from healthy controls. These 
observations are corroborated by higher levels of IL-10 and 
CCL20, two M2-associated cytokines, in the plasma of 
cancer patients. IL-10 is a well-known immune suppressive 
cytokine produced during cancer progression [32]. CCL20 
is involved in promoting tumor growth, migration and EMT 
transition in breast cancer in vitro models [33] and it also 
plays a role in recruiting immature dendritic cells and in 
tumor-promoting Tregs in other cancer types [34]. We also 
found elevated fibronectin (FN1) transcript in CD11b+ cells 
of cancer patients. Interestingly, fibronectin deposition is 
observed in the metastatic niche in preclinical models in 
associated in with recruitment of CD11b+ cells [35] and with 
cancer progression, including of the breast, in human [36]. 
Unfortunately it was not possible to monitor the 
therapy effect on the M2 phenotype by RNASeq due to 
insufficient amounts and low quality material. However, 
we were able to measure selected transcripts for M1 and 
M2 markers in CD11b+ cells and M1 and M2 cytokines 
in the plasma of patients under therapy. Most of them 
Figure 4: Evidence for a M2 activation phenotype of cD11b+ cells in the blood of metastatic breast cancer patients. 
(A) Quantification of the mRNA expression levels of M2 markers CD163, (b) ARG1 and (c) IL-10 in CD11b+ cells derived from the blood 
of healthy donors compare to cancer patients before therapy start. (D) Quantification of mRNA expression levels of M1 markers CCR7, 
(E) CD86 and (F) IL-12α at mRNA level in CD11b+ cells of the same healthy donors and cancer patients. Analysis was performed by real 
time qPCR. All data are represented as mean +/− SD.
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didn’t change or were below detection level (data not 
show). Nevertheless we observed significant and specific 
decrease in the M2 markers ARG1 at mRNA level (albeit 
ARG1 was only significant at day 8) and IL-10 cytokine 
secretion under bevacizumab therapy, and a consistent, 
but not significant, trend in increased M1 markers CD86 
and CCL2 cytokine production. These results suggest that 
bevacizumab could prompt an immune switch from a pro-
tumoral M2 activity toward an anti-tumoral M1 activity. 
Tumor-induced M2 polarization and cytokine production 
may reach beyond local reprogramming occurring in 
the tumor microenvironment and may have systemic 
relevance [28, 37]. 
These observations may have practical implications 
to breast cancer diagnosis, treatment and monitoring. 
Circulating KIT+CD11b+ cells and IL-10 levels (or more 
generally M2/M1 marker ratio) could serve as potential 
biomarkers to follow patient’s response to bevacizumab 
Figure 5: Increased expression of the M2 cytokines IL-10 and ccL20 in the plasma of metastatic breast cancer 
patients and decrease of IL-10 levels by bevacizumab. (A) Quantification of M1 cytokines TNFα, IL-12p70 and CCL2 in plasma 
of healthy donors and cancer patients before therapy start. (b) Quantification of M2 cytokines IL-10 and CCL20 in the plasma of the same 
healthy donors and cancer patients before therapy start. (c) Quantification of CD163, (D) ARG1 and (E) IL-10 mRNA expression variation 
in CD11b+ cells of cancer patient during therapy with paclitaxel ± bevacizumab using real time qPCR. (F) Quantification of IL-10 in the 
plasma of cancer patients during therapy with paclitaxel ± bevacizumab. Cytokines were measured by ELISA. All data are represented as 
mean +/− SD.
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treatment. This might be particularly relevant in 
conditions where bevacizumab effects may be restricted 
to a subset of the patients, as it appears to occur in 
metastatic breast cancer. Their modulation is consistent 
with an immunostimulatory effect of bevacizumab. 
Interestingly, preclinical and clinical evidence suggest 
that response to chemotherapy involves the activation 
of the immune system and induction of an anti-tumor 
immune response [38, 39]. Thus bevacizumab, in 
addition to its anti-angiogenic effects, might provide 
therapeutic benefits by reversing the M2-associated state 
of immunosuppression. Larger studies are needed to test 
this hypothesis. 
Most patients received bisphosphonates (or an 
anti-RANK-L antibody) as part of their therapies due 
to bone metastasis (Table 1), but no correlations were 
observed between marker levels and bisphosphonate 
(or anti-RANK-L) treatment (Supplementary Figures 5 
and 6), except a transient increased mobilization of CEP 
at day 8 of therapy with paclitaxel and bevacizumab. 
Bisphosphonates have been involved in modulation 
of bone-resident macrophage activity including 
reprogramming from tumorigenic M2 status to an 
anti-tumoral M1 status [40]. Bisphosphonate effects 
on circulating CD11b+ cells cannot be confirmed by 
our data (data not show). Also, the limited number of 
patients did not allow drawing an association between a 
particular subtype of breast cancer and circulating cells 
(Supplementary Figure 7). In addition, some patients 
also received in parallel an endocrine therapy based on 
their cancer subtype (Table 1). These treatments also 
did not have any effect on our cells and markers levels 
(data not show). The fact that some patients had primary 
tumor surgery more then 6 months before treatment 
start (Table 1) also did not have any significant impact 
on the observed changes on CEC, CEP, KIT+ CD11b+ 
cells and M2 markers (data not show). It should be 
emphasized that considering the small number of patients 
analyzed, these lack of correlations do not exclude that 
some correlations might be observed in larger patients 
populations.
In summary, we demonstrate that metastatic 
breast cancer patients have an increased frequency of 
circulating KIT+CD11b+ cells, M2-polarized CD11b+ 
cells and elevated levels of the M2 cytokine IL-10 
and CCL20. Compared to paclitaxel monotherapy 
only, co-treatment with bevacizumab significantly 
decreased KIT+CD11b+ cells and IL-10. These 
results warrant the further investigation of changes 
in circulating KIT+CD11b+ cells and IL-10 levels 
as candidate biomarkers of bevacizumab activity in 
metastatic breast cancer and possibly other cancer types. 
They also provide original evidence for a systemic 
immunomodulatory effect of bevacizumab. We are 
planning a larger study to address these questions. 
MAtErIALs AND MEtHODs 
clinical data and material
The study was approved by the regional ethic boards 
of St.Gallen and Zurich, Switzerland. We studied 21 
female patients (Table 1) with metastatic breast cancer who 
received first line treatment of palliative chemotherapy 
with either paclitaxel on day 1, 8 and 15 of a 28 days 
cycle, or paclitaxel (same schedule) in combination with 
bevacizumab on day 1 and 15. From these patients, blood 
samples were collected before administration of the first 
therapy at day 0, and before therapy on day 8 and 15. 
All donors gave written informed consent before study 
entry. Patients were recruited in St.Gallen Kantonspital, 
Zürich Oncozentrum and Tumor- und Brustzentrum 
in Chur upon diagnosis of breast cancer metastasis and 
before starting any new treatment. Samples from 12 age-
matched healthy females were analyzed accordingly. Age 
mean for cancer patient was 56.5 years and for healthy 
donors was 58 years old (all patients were between 
39 and 78 years old). Healthy donors were recruited at 
HFR Hôpital Cantonal Fribourgeois in parallel to breast 
cancer patient recruitment, based on the following criteria: 
age-matched relative to breast cancer patient, no surgical 
intervention in the past 10 years, no regular medications in 
the last 6 months, no previous cancer diagnosis, no chronic 
diseases and normal blood analyses at time of recruitment.
blood processing
Blood was collected using BD Vacutainer® Blood 
Collection EDTA Tubes (Becton Dickinson, Franklin 
Lakes, NJ, USA) following manufacturer’s instructions. 
All following analysis were performed without 24 h after 
blood collection to minimize cell death. Plasma and total 
white blood cells were isolated using BD Vacutainer® 
CPT™ Cell Preparation Tube (Becton Dickinson) with 
Sodium Heparin following manufacturer’s instructions of 
use. Plasma fraction was immediately frozen at −80°C. 
CD11b+ cells were isolated from total blood using 
MACS® separation technique, following manufacturer’s 
instructions. MS columns and anti-human/mouse CD11b 
micro-beads were used. All reagents were from Miltenyi 
Biotec (Bergisch Gladbach, Germany). Isolated CD11b+ 
cells were immediately lysed in RNA stable RLT lysis 
buffer (Qiagen, Venlo, Netherlands) and stored at −80°C.
Flow cytometry
Whole blood staining’s were performed within 
24 hours after blood collection. White blood cells were 
counted using Cell-Dyn Sapphire Hematology System 
(Abbott Diagnostics, Chicago, IL, USA). For CEC and 
CEP staining 5 millions cells per tube were used, while 
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for monocyte and isotype staining’s 1 million cells was 
used. Directly labeled antibodies were added on total 
blood and incubated for 20 minutes at 4°C, followed by 
10 minutes red-blood-cells lysis (Bühlmann Laboratories, 
Schönenbuch, Switzerland) and washing using cold PBS. 
All anti-human antibodies were used at the concen-
tration give in manufacturer’s instructions of use: anti-
CD45-V450, anti-CD146-Pe, anti-CD31-AlexaFluo 647, 
anti-CD34-PeCy7, anti-VEGFR2-Pe, anti-CD11b-V450, 
anti-CD64-FITC, anti-JAM1-Pe, anti-TIE2-AlexaFluo 647, 
anti-KIT-PeCy7, anti-CD195-Pe, mouse IgG2a-AlexaFluor 
647, mouse IgG1-Pe, mouse IgG1-PeCy7, mouse IgG1-
APC, mouse IgG2a-Pe, 7AAD (all from Becton Dickinson), 
Syto16 (Life Technologies, Carlsbad, CA, USA), anti-
CD133-APC (Miltenyi), anti-VEGFR1-APC (R & D 
Biosystems, Minneapolis, MN, USA). 
BD FACSCanto II (Becton Dickinson) instrument 
was used to perform experiments and FlowJo 9.8.3 
(Treestar Inc., Ashland, OR, USA) software was used to 
analyze all data. 
ELIsA
For TNF-α, IL-12p70, IL-10, CCL20 and CCL2 
quantification in plasma ELISA MAX Deluxe assays 
from Biolegend (San Diego, CA, USA) was used 
following manufacturer’s instructions. Each sample was 
run in triplicate and absorption was measured at 450 nm 
(VICTOR X3 Reader, PerkinElmer, Waltham, MA, USA).
real-time qPcr
Total RNA from CD11b+ isolated cells was 
extracted using the RNeasy Mini kit from Qiagen. The 
quality and quantity of all RNA samples were examined 
by Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA) and NanoDrop (Witec AG, 
Luzern, Switzerland). Total RNA was retro-transcribed 
using Ovation Nugen RNASeq System v2 kit following 
manufacturer’s instructions (Nugen, San Carlos, CA, 
USA) using 15 ng of total RNA. cDNA was subjected 
to amplification by real time qPCR with the StepOne 
SYBR System (Life Technologies) using the following 
primer pairs (Eurofins Genomics, Huntsville, AL, USA) 
at the indicated hybridization temperatures:  GAPDH 
58°C (Fw-TCTTCTTTTGCGTCGCCAGC, Rev-GATT 
TTGGAGGGATCTCGCTCCT), CCR7 58°C (Fw- ATG 
GACCTGGGGAAACCAAT, Rev- TGATAGGGAGGAA 
CCAGGCT), CD86 58°C (Fw- TCATTGCCGAGGAA 
GGCTTG, Rev- CTCCATTGTGTTGGTTCCACATT), IL-
12a 60°C (Fw- TTCCCATGCCTTCACCACTC, Rev- ACT 
CCCATTAGTTATGAAAGAGGTC), CD163 58°C (Fw- 
GCGGCTTGCAGTTTCCTCAA, Rev- CTCAGAATG 
GCCTCCTTTTCCA), ARG1 58°C (Fw- GGAGTC 
ATCTGGGTGGATGC, Rev- CTGGCACATCGGGAATC 
TTTC), IL-10 58°C (Fw- CGAGATGCCTTCAGCA 
GAGT, Rev- AATCGATGACAGCGCCGTAG), KIT 57°C 
(Fw- GATTATCCCAAGTCTGAGAATGAA, Rev- CGTC 
AGAATTGGACACTAGGA). FN1 52°C (Fw- ACTTC 
GACAGGACCACTTGA, Rev- TCAAATTGGAGATT 
CATGGGA). Real-time PCR data were then analyzed 
using the comparative Ct method [41]. 
Gene expression analysis by rNAseq
RNASeq libraries preparation, data sequencing 
and bioinformatics analysis was performed following 
previously published methodology [42]. But purity-filtered 
reads were adapted and quality trimmed wit Cutadapt 
(v.1.3), filtered for low complexity with PRINSEQ 
(v.0.20.3) and aligned against Homo sapiens.GRCh37.75 
genome using TopHat (v.2.0.9) [43, 44]. Quality of the 
RNASeq data alignment was assessed using RSeQC 
(v.2.3.7) [45]. The number of read counts per gene 
locus was summarized with htseq-count (v.0.6.1) using 
Homo sapiens.GRCh37.75 gene annotation [46]. Data 
normalization and differential expression analysis were 
performed in R (v.3.1.1), using Bioconductor packages 
DESeq2 (v.1.6.2) [47]. The 15996 genes with at least 1 
count per million in at least one sample were kept for 
statistical analysis. Gene Ontology (GO) analysis was 
performed using Gorilla [48] and representations were 
generated using REVIGO [49]. Significant enriched GO 
terms were identified after Bonferroni correction (P value 
< 4.13e-06). The complete data set is publicly available at 
GEO through the accession number GSE70404.
statistical analysis
Acquired data were analyzed and graphics were 
generated using Prism Software (GraphPad, La Jolla, 
CA, USA). Statistical comparisons were performed by 
two-way ANOVA with Bonferroni post-test. Highest and 
lowest values from each group were excluded. Results 
were considered to be significantly from p < 0.05. In the 
figures the various p values thresholds are presented as 
follow: ≤ 0.05 =*, ≤ 0.01 =**, ≤ 0.001 =***, ≤ 0.0001 =****.
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